Analysis of a novel phage as a promising biological agent targeting multidrug resistant Klebsiella pneumoniae
- PMID: 40044971
- PMCID: PMC11882492
- DOI: 10.1186/s13568-025-01846-0
Analysis of a novel phage as a promising biological agent targeting multidrug resistant Klebsiella pneumoniae
Abstract
The rise of deaths by resistant bacteria is a global threat to public health systems. Klebsiella pneumoniae is a virulent pathogen that causes serious nosocomial infections. The major obstacle to bacterial treatment is antibiotic resistance, which necessitates the introducing of alternative therapies. Phage therapy has been regarded as a promising avenue to fight multidrug-resistant (MDR) pathogens. In the current study, a novel phage vB_KpnP_KP17 was isolated from sewage, and its lytic potential was investigated against K. pneumoniae. The isolated phage vB_KpnP_kP17 was lytic to 17.5% of tested K. pneumoniae isolates. One step growth curve indicated a virulent phage with a short latent period (20 min) and large burst size (331 PFU/cell). Additionally, vB_KpnP_kP17 maintained its activity against planktonic cells over a wide range of pH, temperature and UV irradiation intervals. The potential of vB_KpnP_KP17 as antibiofilm agent was revealed by the biofilm inhibition assay. The isolated phage vB_KpnP_KP17 at multiplicity of infection (MOI) of 10 inhibited more than 50% of attached biofilms of tested K. pneumoniae isolates. The genome of vB_KpnP_kP17 was characterized and found to be a linear dsDNA of 39,936 bp in length and GC content of 52.85%. Additionally, the absence of toxicity, virulence and antibiotic resistance genes further confirms the safety of vB_KpnP_KP17 for clinical applications. These characteristics make vB_KpnP_KP17 of a potential therapeutic value to manage MDR K. pneumoniae infections. Additionally, the formulation of vB_KpnP_KP17 in a cocktail with other lytic phages or with antibiotics could be applied to further limit biofilm-producing K. pneumoniae infections.
Keywords: Klebsiella pneumoniae; Bacteriophage; Biofilm; Genomic characterization; Multidrug resistance; Phage therapy.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The current study was conducted in accordance with the Declaration of Helsinki.). Consent for publication: Not applicable. Competing interest: The authors declare no competing financial interest.
Figures
References
-
- Abedon ST (2023) Evolution of bacteriophage latent period length. In: Dickins TE, Dickins BJA (eds) Evolutionary biology: contemporary and historical reflections upon core theory. Springer, Cham, pp 375–426. 10.1007/978-3-031-22028-9_23
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous
